OGM Is in the Autism Initiative Leading cente
Post# of 99
(Total Views: 81)
Posted On: 09/23/2025 8:38:04 AM
OGM Is in the Autism Initiative
Leading centers (CHOP, Kennedy Krieger, NIMH, HudsonAlpha, UCSD, Baylor, Greenwood) are piloting or deploying OGM to uncover structural variants in autism cohorts. Their findings feed NIH databases and consortia like the Autism Sequencing Consortium, even if the NIH press office never mentions “Bionano Genomics” by name.
The White House and NIH typically frame large-scale research initiatives in broad, technology-agnostic terms to maintain neutrality and avoid the appearance of vendor favoritism. They highlight goals like “turbocharging” autism research through better data collection, sharing, and analysis, rather than listing every method or commercial platform that investigators might use.
Similarly, the recent op-ed announcing the Trump Administration’s autism strategy focuses on three pillars, FDA-recognized treatment pathways, risk communication, and targeted research investments, without specifying laboratory techniques or proprietary tools. This high-level language helps secure broad bipartisan support and keeps the door open to multiple technologies.
Leading centers (CHOP, Kennedy Krieger, NIMH, HudsonAlpha, UCSD, Baylor, Greenwood) are piloting or deploying OGM to uncover structural variants in autism cohorts. Their findings feed NIH databases and consortia like the Autism Sequencing Consortium, even if the NIH press office never mentions “Bionano Genomics” by name.
The White House and NIH typically frame large-scale research initiatives in broad, technology-agnostic terms to maintain neutrality and avoid the appearance of vendor favoritism. They highlight goals like “turbocharging” autism research through better data collection, sharing, and analysis, rather than listing every method or commercial platform that investigators might use.
Similarly, the recent op-ed announcing the Trump Administration’s autism strategy focuses on three pillars, FDA-recognized treatment pathways, risk communication, and targeted research investments, without specifying laboratory techniques or proprietary tools. This high-level language helps secure broad bipartisan support and keeps the door open to multiple technologies.
(0)
(0)